Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.
Filter by yearAll 2022 2021 2020 2019 2018 2017 2016 2015 2014 2012 2011 2010 2009 2008 2007 2006 2005 2001 2000 1998 1997 1996 1995 1994 1993 1992 1991 1990 1988 1986 1985
Deiana, S, et al. (2008) Methylthioninium chloride versus rivastigmine and their co-administration efficacy in reversing scopolamine-induced cognitive deficits in a pharmacological mouse model of Alzheimer's disease. Available at Psychopharmacology.
Harrington, C, et al. (2008) Methylthioninium chloride (MTC) acts as a Tau aggregation inhibitor (TAI) in a cellular model and reverses Tau pathology in transgenic mouse models of Alzheimer's disease. Available at Alzheimer's & Dementia.
Luna-Muñoz, J, et al. (2008) Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints. Available at Acta Neuropathologica
Melis, V, et al. (2008) Reversal of spatial problem-solving cognitive deficit in a transgenic mouse line overexpressing the repeat domain of Tau by treatment with the Tau aggregation inhibitor methylthioninium chloride. Available at Alzheimer's & Dementia.
Murray, A.D. et al. (2008) Tau Aggregation Inhibitor (TAI) therapy with remberTM changes glucose metabolism in the medial temporal lobes in mild and moderate Alzheimer's disease (AD). Available at Alzheimer's & Dementia.